These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 8113631)
1. Treatment of advanced pancreatic cancer with high-dose octreotide. Friess H; Büchler M; Ebert M; Malfertheiner P; Dennler HJ; Beger HG Int J Pancreatol; 1993 Dec; 14(3):290-1. PubMed ID: 8113631 [No Abstract] [Full Text] [Related]
2. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Rosenberg L; Barkun AN; Denis MH; Pollak M Cancer; 1995 Jan; 75(1):23-8. PubMed ID: 7804972 [TBL] [Abstract][Full Text] [Related]
3. Role of octreotide in the treatment of pancreatic cancer. Ebert M; Friess H; Beger HG; Büchler MW Digestion; 1994; 55 Suppl 1():48-51. PubMed ID: 8132137 [TBL] [Abstract][Full Text] [Related]
4. Octreotide acetate long-acting release in treatment of pancreatic neuroendocrine tumors. Zhang S; Li YX; Li NS; Li WH; Zhu HJ; Gu F; Wang H Chin Med J (Engl); 2009 Jul; 122(13):1582-4. PubMed ID: 19719952 [No Abstract] [Full Text] [Related]
5. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study. Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733 [TBL] [Abstract][Full Text] [Related]
6. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen]. Wenger FA; Zieren HU; Jacobi CA; Müller JM Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1348-50. PubMed ID: 9931878 [TBL] [Abstract][Full Text] [Related]
7. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours. Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100 [TBL] [Abstract][Full Text] [Related]
8. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Homma H; Doi T; Mezawa S; Takada K; Kukitsu T; Oku T; Akiyama T; Kusakabe T; Miyanishi K; Niitsu Y Cancer; 2000 Jul; 89(2):303-13. PubMed ID: 10918160 [TBL] [Abstract][Full Text] [Related]
9. [Insulinoma effectively controlled with low dose of octreotide acetate]. Fukuoka K; Matsushita M; Murase T; Yamamori I Nihon Naika Gakkai Zasshi; 2007 Dec; 96(12):2786-8. PubMed ID: 18203414 [No Abstract] [Full Text] [Related]
10. Short-term octreotide treatment induces apoptosis in human pancreatic cancer xenografts. Zalatnai A; Bocsi J In Vivo; 2006; 20(4):549-52. PubMed ID: 16900788 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of pancreatic apudomas with a somatostatin analog SMS 201-995]. Varas Lorenzo MJ Med Clin (Barc); 1988 Dec; 91(20):796. PubMed ID: 3236932 [No Abstract] [Full Text] [Related]
12. [Metastatic breast carcinoma with neuroendocrine differentiation--its combined therapy with tamoxifen and the somatostatin analog octreotide]. Rischke HC; Staib-Sebler E; Mose S; Adams SW; Herrmann G; Böttcher HD; Lorenz M Dtsch Med Wochenschr; 1999 Feb; 124(7):182-6. PubMed ID: 10093577 [TBL] [Abstract][Full Text] [Related]
13. In vitro chemosensitivity of human pancreatic cancer cell lines. Sawabe Y; Yamagishi H; Yamaguchi N; Yamamura Y; Oka T Int J Pancreatol; 1996 Dec; 20(3):185-90. PubMed ID: 9013279 [TBL] [Abstract][Full Text] [Related]
14. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. Topkan E; Karaoglu A Oncology; 2006; 71(5-6):354-60. PubMed ID: 17873499 [TBL] [Abstract][Full Text] [Related]
15. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice. Weckbecker G; Raulf F; Bodmer D; Bruns C Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482 [TBL] [Abstract][Full Text] [Related]
16. Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma. Healy ML; Dawson SJ; Murray RM; Zalcberg J; Jefford M Intern Med J; 2007 Jun; 37(6):406-9. PubMed ID: 17535385 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Okada S; Sakata Y; Matsuno S; Kurihara M; Sasaki Y; Ohashi Y; Taguchi T Br J Cancer; 1999 May; 80(3-4):438-43. PubMed ID: 10408850 [TBL] [Abstract][Full Text] [Related]
18. Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor. Grande E; José Díez J; Pachón V; Angeles Vaz M; Longo F; Guillén C; García de Paredes ML; Carrato A Anticancer Drugs; 2011 Jun; 22(5):477-9. PubMed ID: 21346550 [TBL] [Abstract][Full Text] [Related]
19. Controversial issues in the management of pancreatic cancer: Part Two. A debate held at St Mary's Hospital, London on 18 November 1993. Glazer G; Coulter C; Crofton ME; Gedroyc WM; Johnson CD; Mallinson CN; Russell RC; Steer ML; Summerfield JA; Williamson RC Ann R Coll Surg Engl; 1995 May; 77(3):174-80. PubMed ID: 7598413 [No Abstract] [Full Text] [Related]
20. [Octreotide in the treatment of advanced pancreatic tumor. Preliminary study]. Cirillo F; Bottini A; Brunelli A; Zuffada S; Bassi M; Filippini L; Alquati P Minerva Chir; 1998 Dec; 53(12):979-85. PubMed ID: 10210927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]